Fig. 5
From: Therapeutic potential of PLK1 inhibition in triple-negative breast cancer
a Immunohistochemistry of PLK1 in normal mammary gland. b Immunohistochemistry of PLK1 in benign tumors. c Immunohistochemistry of PLK1 in luminal A, luminal B, HER-2 positive or TNBC tissues (# shows each patient). d The high magnification image of TNBC tissue immunostained with anti-PLK1 antibody. Arrows show condensed chromosomes. e Immunohistochemistry of Ki67 in luminal A, luminal B, HER-2 positive or TNBC tissues. f A box plot of semi-quantified Quickscore of PLK1 in normal mammary glands, benign tumor (three fibroadenoma cases, one benign plyllodes case and one intraductal papilloma case), luminal A, luminal B, HER-2 positive and TNBC. g A box plot of quantified Ki67-positive cells in the luminal A, luminal B, HER-2 positive and TNBC tissues. h The correlation of the Quickscore of PLK1 and rate of Ki67-positive cells. Statistical significance was calculated by one-way ANOVA followed by Tukey’s test. *p < 0.05, **p < 0.01. N = 5
